Concepts (198)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| HIV Infections | 41 | 2022 | 2134 | 4.620 |
Why?
|
| Anti-Retroviral Agents | 12 | 2018 | 148 | 3.310 |
Why?
|
| Infectious Disease Transmission, Vertical | 12 | 2020 | 234 | 2.460 |
Why?
|
| Pregnancy Complications, Infectious | 11 | 2021 | 419 | 1.770 |
Why?
|
| Malawi | 28 | 2022 | 378 | 1.760 |
Why?
|
| Child Health Services | 5 | 2018 | 82 | 1.410 |
Why?
|
| Health Personnel | 8 | 2021 | 625 | 1.080 |
Why?
|
| Anti-HIV Agents | 13 | 2021 | 350 | 1.070 |
Why?
|
| Counseling | 6 | 2021 | 381 | 1.010 |
Why?
|
| Mass Screening | 7 | 2020 | 1509 | 1.010 |
Why?
|
| Tuberculosis | 3 | 2020 | 548 | 0.870 |
Why?
|
| Antiretroviral Therapy, Highly Active | 4 | 2016 | 317 | 0.720 |
Why?
|
| Community Health Workers | 4 | 2017 | 57 | 0.690 |
Why?
|
| Acquired Immunodeficiency Syndrome | 2 | 2018 | 362 | 0.680 |
Why?
|
| Burnout, Professional | 2 | 2019 | 205 | 0.670 |
Why?
|
| Infectious Disease Transmission, Patient-to-Professional | 1 | 2017 | 58 | 0.610 |
Why?
|
| Family Characteristics | 1 | 2017 | 102 | 0.580 |
Why?
|
| Community Health Services | 1 | 2017 | 126 | 0.550 |
Why?
|
| Infection Control | 1 | 2017 | 270 | 0.530 |
Why?
|
| Health Policy | 1 | 2018 | 291 | 0.530 |
Why?
|
| Hearing Loss | 1 | 2016 | 153 | 0.510 |
Why?
|
| Quality of Health Care | 2 | 2018 | 621 | 0.500 |
Why?
|
| Ambulatory Care Facilities | 2 | 2017 | 289 | 0.490 |
Why?
|
| Chemoprevention | 1 | 2015 | 241 | 0.480 |
Why?
|
| Social Work | 1 | 2013 | 24 | 0.470 |
Why?
|
| Antitubercular Agents | 1 | 2016 | 318 | 0.470 |
Why?
|
| Cross Infection | 1 | 2017 | 544 | 0.450 |
Why?
|
| Pregnancy | 17 | 2022 | 7573 | 0.430 |
Why?
|
| Breast Feeding | 1 | 2013 | 239 | 0.410 |
Why?
|
| Sarcoma, Kaposi | 3 | 2018 | 187 | 0.400 |
Why?
|
| Medication Adherence | 5 | 2021 | 492 | 0.400 |
Why?
|
| Child | 22 | 2021 | 29154 | 0.390 |
Why?
|
| Pregnant Women | 5 | 2022 | 162 | 0.340 |
Why?
|
| AIDS Serodiagnosis | 3 | 2019 | 61 | 0.330 |
Why?
|
| Child, Preschool | 14 | 2019 | 16273 | 0.310 |
Why?
|
| Leishmania infantum | 2 | 2006 | 6 | 0.300 |
Why?
|
| Leishmaniasis, Visceral | 2 | 2006 | 13 | 0.300 |
Why?
|
| Adolescent | 17 | 2020 | 31252 | 0.300 |
Why?
|
| Infant | 15 | 2019 | 13310 | 0.290 |
Why?
|
| Protozoan Vaccines | 2 | 2006 | 91 | 0.280 |
Why?
|
| Early Diagnosis | 3 | 2018 | 298 | 0.280 |
Why?
|
| Africa South of the Sahara | 3 | 2020 | 101 | 0.270 |
Why?
|
| Humans | 43 | 2022 | 261506 | 0.250 |
Why?
|
| Female | 33 | 2022 | 141928 | 0.240 |
Why?
|
| Cross-Sectional Studies | 6 | 2022 | 4314 | 0.240 |
Why?
|
| Depression | 4 | 2022 | 1715 | 0.240 |
Why?
|
| Long-Term Care | 2 | 2013 | 83 | 0.230 |
Why?
|
| Preventive Health Services | 2 | 2013 | 75 | 0.220 |
Why?
|
| Infant, Newborn | 8 | 2021 | 8223 | 0.220 |
Why?
|
| Intimate Partner Violence | 1 | 2021 | 26 | 0.200 |
Why?
|
| Health Services Accessibility | 3 | 2017 | 761 | 0.200 |
Why?
|
| Male | 23 | 2019 | 123000 | 0.190 |
Why?
|
| Adult | 17 | 2022 | 77950 | 0.190 |
Why?
|
| Delivery of Health Care, Integrated | 2 | 2013 | 164 | 0.190 |
Why?
|
| Type D Personality | 1 | 2019 | 2 | 0.180 |
Why?
|
| Audiovisual Aids | 1 | 2020 | 42 | 0.180 |
Why?
|
| Viral Load | 2 | 2018 | 493 | 0.180 |
Why?
|
| Marital Status | 1 | 2019 | 98 | 0.180 |
Why?
|
| Pediatrics | 2 | 2018 | 1141 | 0.170 |
Why?
|
| Syphilis | 1 | 2019 | 61 | 0.160 |
Why?
|
| Job Satisfaction | 1 | 2019 | 122 | 0.160 |
Why?
|
| Herpesviridae Infections | 1 | 2018 | 175 | 0.150 |
Why?
|
| Audiometry, Pure-Tone | 1 | 2016 | 32 | 0.150 |
Why?
|
| Health Services Research | 1 | 2018 | 233 | 0.140 |
Why?
|
| Young Adult | 8 | 2019 | 21445 | 0.130 |
Why?
|
| Antigens, Protozoan | 2 | 2006 | 66 | 0.130 |
Why?
|
| Self Report | 4 | 2020 | 756 | 0.130 |
Why?
|
| Maternal Health Services | 2 | 2013 | 34 | 0.130 |
Why?
|
| Mental Disorders | 1 | 2022 | 862 | 0.120 |
Why?
|
| Coinfection | 1 | 2016 | 189 | 0.120 |
Why?
|
| Family | 1 | 2018 | 736 | 0.120 |
Why?
|
| Sensitivity and Specificity | 2 | 2020 | 4971 | 0.120 |
Why?
|
| Sex Factors | 1 | 2019 | 2139 | 0.120 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2019 | 573 | 0.120 |
Why?
|
| Interleukin-6 | 1 | 2018 | 1038 | 0.120 |
Why?
|
| Prevalence | 2 | 2019 | 3260 | 0.120 |
Why?
|
| Drug Utilization | 1 | 2015 | 179 | 0.120 |
Why?
|
| Child, Orphaned | 1 | 2013 | 18 | 0.120 |
Why?
|
| Mycobacterium tuberculosis | 1 | 2017 | 426 | 0.110 |
Why?
|
| Chi-Square Distribution | 1 | 2016 | 1323 | 0.110 |
Why?
|
| Public Policy | 1 | 2013 | 60 | 0.110 |
Why?
|
| Public Health | 1 | 2016 | 299 | 0.110 |
Why?
|
| Cause of Death | 1 | 2016 | 752 | 0.110 |
Why?
|
| Immunization Programs | 1 | 2013 | 73 | 0.110 |
Why?
|
| Surveys and Questionnaires | 3 | 2021 | 5687 | 0.110 |
Why?
|
| Multivariate Analysis | 2 | 2018 | 4298 | 0.110 |
Why?
|
| Risk Assessment | 2 | 2016 | 6869 | 0.110 |
Why?
|
| Health Resources | 1 | 2013 | 168 | 0.110 |
Why?
|
| Risk Factors | 3 | 2019 | 17523 | 0.100 |
Why?
|
| Vulnerable Populations | 1 | 2013 | 167 | 0.100 |
Why?
|
| Lost to Follow-Up | 3 | 2018 | 34 | 0.100 |
Why?
|
| Developing Countries | 1 | 2013 | 315 | 0.100 |
Why?
|
| Odds Ratio | 1 | 2016 | 2316 | 0.100 |
Why?
|
| Social Support | 1 | 2013 | 560 | 0.090 |
Why?
|
| Treatment Adherence and Compliance | 2 | 2020 | 12 | 0.090 |
Why?
|
| Contact Tracing | 2 | 2021 | 56 | 0.090 |
Why?
|
| Population Surveillance | 1 | 2013 | 627 | 0.090 |
Why?
|
| Disease Models, Animal | 1 | 2003 | 7222 | 0.090 |
Why?
|
| Psychometrics | 1 | 2014 | 937 | 0.090 |
Why?
|
| Malnutrition | 1 | 2012 | 218 | 0.080 |
Why?
|
| Quality Assurance, Health Care | 1 | 2013 | 585 | 0.080 |
Why?
|
| Capacity Building | 2 | 2021 | 30 | 0.080 |
Why?
|
| Electronic Health Records | 1 | 2016 | 929 | 0.080 |
Why?
|
| CD4 Lymphocyte Count | 3 | 2013 | 297 | 0.080 |
Why?
|
| Health Care Costs | 1 | 2013 | 674 | 0.080 |
Why?
|
| Pregnancy Complications | 1 | 2012 | 526 | 0.070 |
Why?
|
| Pilot Projects | 3 | 2021 | 2803 | 0.070 |
Why?
|
| Age Factors | 1 | 2016 | 5377 | 0.070 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2016 | 6207 | 0.070 |
Why?
|
| Dog Diseases | 1 | 2006 | 73 | 0.070 |
Why?
|
| Time Factors | 2 | 2016 | 12926 | 0.070 |
Why?
|
| Disclosure | 2 | 2017 | 181 | 0.060 |
Why?
|
| Polymerase Chain Reaction | 1 | 2011 | 3203 | 0.060 |
Why?
|
| Treatment Outcome | 2 | 2016 | 32848 | 0.060 |
Why?
|
| Prenatal Care | 2 | 2019 | 325 | 0.060 |
Why?
|
| Psychiatric Status Rating Scales | 2 | 2018 | 901 | 0.060 |
Why?
|
| Administration, Cutaneous | 1 | 2003 | 141 | 0.050 |
Why?
|
| Lymphoid Tissue | 1 | 2003 | 95 | 0.050 |
Why?
|
| Quality of Life | 1 | 2016 | 4532 | 0.050 |
Why?
|
| World Health Organization | 2 | 2013 | 316 | 0.050 |
Why?
|
| Program Development | 2 | 2013 | 261 | 0.050 |
Why?
|
| Retrospective Studies | 5 | 2016 | 37905 | 0.050 |
Why?
|
| Injections, Intravenous | 1 | 2003 | 573 | 0.050 |
Why?
|
| Virulence | 1 | 2003 | 323 | 0.050 |
Why?
|
| Tanzania | 1 | 2020 | 68 | 0.050 |
Why?
|
| HIV-1 | 2 | 2016 | 653 | 0.040 |
Why?
|
| Endemic Diseases | 1 | 2018 | 67 | 0.040 |
Why?
|
| Sexual Partners | 1 | 2019 | 112 | 0.040 |
Why?
|
| Global Health | 2 | 2013 | 657 | 0.040 |
Why?
|
| Depersonalization | 1 | 2018 | 15 | 0.040 |
Why?
|
| Africa | 1 | 2018 | 142 | 0.040 |
Why?
|
| Multicenter Studies as Topic | 1 | 2020 | 543 | 0.040 |
Why?
|
| Herpesvirus 8, Human | 1 | 2018 | 102 | 0.040 |
Why?
|
| Family Health | 1 | 2019 | 325 | 0.040 |
Why?
|
| Mice, Inbred BALB C | 1 | 2003 | 2314 | 0.040 |
Why?
|
| Video Recording | 1 | 2019 | 267 | 0.040 |
Why?
|
| Healthcare Disparities | 2 | 2013 | 598 | 0.040 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2019 | 173 | 0.040 |
Why?
|
| Stereotyping | 1 | 2017 | 23 | 0.040 |
Why?
|
| Logistic Models | 2 | 2017 | 3441 | 0.040 |
Why?
|
| Skin | 1 | 2003 | 1259 | 0.040 |
Why?
|
| Virus Activation | 1 | 2018 | 228 | 0.040 |
Why?
|
| Drug Prescriptions | 1 | 2018 | 289 | 0.030 |
Why?
|
| Bullying | 1 | 2015 | 15 | 0.030 |
Why?
|
| Pregnancy Outcome | 1 | 2019 | 643 | 0.030 |
Why?
|
| Epidemiologic Methods | 1 | 2015 | 254 | 0.030 |
Why?
|
| Bleomycin | 1 | 2016 | 467 | 0.030 |
Why?
|
| Regression Analysis | 1 | 2018 | 1546 | 0.030 |
Why?
|
| Delivery of Health Care | 1 | 2021 | 860 | 0.030 |
Why?
|
| United Nations | 1 | 2013 | 11 | 0.030 |
Why?
|
| Schools | 1 | 2015 | 233 | 0.030 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2016 | 15862 | 0.030 |
Why?
|
| Risk | 1 | 2017 | 1972 | 0.030 |
Why?
|
| Premedication | 1 | 2013 | 135 | 0.030 |
Why?
|
| Lesotho | 1 | 2012 | 17 | 0.030 |
Why?
|
| Community Networks | 1 | 2012 | 45 | 0.030 |
Why?
|
| Food, Formulated | 1 | 2012 | 50 | 0.030 |
Why?
|
| Mental Health | 1 | 2015 | 415 | 0.030 |
Why?
|
| Vincristine | 1 | 2016 | 1511 | 0.030 |
Why?
|
| Socioeconomic Factors | 1 | 2016 | 1225 | 0.030 |
Why?
|
| History, 21st Century | 1 | 2013 | 441 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2020 | 2594 | 0.030 |
Why?
|
| Health Planning Guidelines | 1 | 2011 | 58 | 0.020 |
Why?
|
| Outpatients | 1 | 2014 | 462 | 0.020 |
Why?
|
| Attitude of Health Personnel | 1 | 2018 | 918 | 0.020 |
Why?
|
| History, 20th Century | 1 | 2013 | 574 | 0.020 |
Why?
|
| ROC Curve | 1 | 2014 | 1183 | 0.020 |
Why?
|
| Prenatal Exposure Delayed Effects | 1 | 2013 | 268 | 0.020 |
Why?
|
| HIV Antibodies | 1 | 2011 | 102 | 0.020 |
Why?
|
| Nutritional Status | 1 | 2012 | 337 | 0.020 |
Why?
|
| Infant Mortality | 1 | 2011 | 186 | 0.020 |
Why?
|
| Remission Induction | 1 | 2016 | 3569 | 0.020 |
Why?
|
| Program Evaluation | 1 | 2012 | 597 | 0.020 |
Why?
|
| Cost-Benefit Analysis | 1 | 2013 | 945 | 0.020 |
Why?
|
| Health Promotion | 1 | 2013 | 502 | 0.020 |
Why?
|
| Patient Compliance | 1 | 2013 | 667 | 0.020 |
Why?
|
| Feeding Behavior | 1 | 2013 | 808 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2012 | 1945 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2018 | 9180 | 0.020 |
Why?
|
| Antibodies, Protozoan | 1 | 2006 | 87 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2014 | 4892 | 0.020 |
Why?
|
| Th1 Cells | 1 | 2006 | 250 | 0.020 |
Why?
|
| Dogs | 1 | 2006 | 1155 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2018 | 12873 | 0.010 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2006 | 709 | 0.010 |
Why?
|
| Interferon-gamma | 1 | 2006 | 1144 | 0.010 |
Why?
|
| Neoplasm Staging | 1 | 2017 | 13658 | 0.010 |
Why?
|
| Animals | 2 | 2006 | 59536 | 0.010 |
Why?
|
| Mice | 1 | 2003 | 34495 | 0.010 |
Why?
|
| Lymphocyte Activation | 1 | 2006 | 1688 | 0.010 |
Why?
|
| Disease-Free Survival | 1 | 2013 | 10001 | 0.010 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2006 | 1538 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2016 | 14889 | 0.010 |
Why?
|
| Combined Modality Therapy | 1 | 2012 | 8865 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2011 | 9244 | 0.010 |
Why?
|
| Prognosis | 1 | 2016 | 21713 | 0.010 |
Why?
|
| Cytokines | 1 | 2006 | 2809 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2006 | 6150 | 0.010 |
Why?
|